• June 15, 2026
    Otsuka Pharmaceutical
    Otsuka Pharmaceutical Completes Acquisition of Transcend Therapeutics
  • June 11, 2026
    Otsuka Foods
    Otsuka Foods’ Biwako Research Institute Develops “Oishisa LENS,” an AI System That Predicts Flavor Profiles and Recipes to Secure Expertise Transfer and Enhance Product Design 58 Years After the Brand’s Launch, Preserving Bon Curry’s Signature Taste for the Next Generation
  • June 5, 2026
    Otsuka Pharmaceutical
    Otsuka Establishes “Heatstroke Countermeasure Industry-Government-Academia Consortium” with the National Institute for Environmental Studies and Other Partners
  • June 5, 2026
    Otsuka Pharmaceutical
    Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT (sibeprenlimab-szsi) Preserved Kidney Function Over 12 Months in IgA Nephropathy (IgAN)
  • May 29, 2026
    Otsuka Pharmaceutical
    Otsuka Presents New Phase 3 Post Hoc Analyses of Centanafadine Highlighting Improvement in Executive Function and Emotional Dysregulation in Adults with ADHD at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting